Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma
NCT ID: NCT00020566
Last Updated: 2014-06-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
1200 participants
INTERVENTIONAL
2001-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This randomized phase III trial is studying different combination chemotherapy regimens to see how well they work when given with or without peripheral stem cell transplantation, radiation therapy, and/or surgery in treating patients with Ewing's sarcoma.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma
NCT00002516
Combination Chemotherapy and Radiation Therapy in Treating Patients With Peripheral Neuroectodermal Tumors, Ewing's Sarcoma, Wilms' Tumor, or Bone Cancer
NCT00002466
Whole-Body Radiation Therapy, Systemic Chemotherapy, and High-Dose Chemotherapy Followed By Stem Cell Rescue in Treating Patients With Poor-Risk Ewing Sarcoma
NCT01795430
Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
NCT00006734
Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Radiation Therapy in Treating Patients With Ewing's Sarcoma, Peripheral Primitive Neuroectodermal Tumor, or Rhabdomyosarcoma
NCT00003081
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Primary
* Compare the event-free and overall survival of patients with tumor of the Ewing's family treated with standard induction chemotherapy comprising vincristine, dactinomycin, ifosfamide and etoposide (VIDE) followed by consolidation chemotherapy comprising vincristine, dactinomycin, and ifosfamide versus high-dose busulfan and melphalan (Bu-Mel) followed by autologous peripheral blood stem cell (PBSC) transplantation with or without radiotherapy and/or surgery.
Secondary
* Determine the prognostic significance of EWS-Flil transcript in these patients.
* Determine the frequency and prognostic value of minimal disease in bone marrow and PBSC, as determined by the presence or absence of EWS-Flil transcript, in these patients.
* Determine the feasibility and toxicity of VIDE induction chemotherapy in these patients.
* Determine the response of these patients to VIDE induction chemotherapy.
* Determine the feasibility and toxicity of VAI consolodation chemotherapy in these patients.
* Determine the feasibility and toxicity of Bu-Mel consolodation chemotherapy in these patients.
* Determine event-free survival and overall survival of patients treated with these regimens by prognostic group analysis.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age and local treatment of the primary tumor (yes vs no).
Patients receive induction chemotherapy comprising vincristine IV on day 1 and ifosfamide IV over 3 hours, doxorubicin IV over 4 hours, and etoposide IV over 1 hour on days 1-3 (VIDE). Treatment repeats every 21 days for 4 courses in the absence of unacceptable toxicity. Peripheral blood stem cells (PBSC) are collected after course 3 and/or 4. Patients are evaluated after course 4. Patients in need of early radiotherapy due to an axial tumor or patients who require radiotherapy to the brain and/or spinal cord (at any time during study) are assigned to group 1. Patients not needing early radiotherapy are assigned to group 2.
* Group 1: Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
* Group 2: Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients are randomized to 1 of 2 consolidation therapy arms.
* Arm I: Patients receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
* Arm II: Patients receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
Patients are followed every 3 months for 4 years, every 6 months for 1 year, and then periodically thereafter.
Peer Reviewed and Funded or Endorsed by Cancer Research UK
PROJECTED ACCRUAL: Approximately 1,200 patients will be accrued for this study within approximately 7 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1
Patients receive 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Patients requiring radiotherapy to the axial tumor also undergo concurrent radiotherapy 5 days a week. Some patients may then undergo surgical resection of the tumor. All patients will then receive vincristine IV on day 1 and dactinomycin IV and ifosfamide IV over 3 hours on days 1 and 2 (VAI). Treatment repeats every 21 days for 8 courses (courses 7-14). Patients requiring radiotherapy to the brain and/or spinal cord also undergo concurrent radiotherapy.
dactinomycin
Given IV
doxorubicin hydrochloride
Given IV
etoposide
Given IV
ifosfamide
Given IV
vincristine sulfate
Given IV
conventional surgery
Given to patients deemed to require it
radiation therapy
Given to patients deemed to require it
Group 2, arm I
Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive 7 additional courses of VAI chemotherapy (courses 8-14). Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent whole-lung radiotherapy for 6-12 days.
dactinomycin
Given IV
doxorubicin hydrochloride
Given IV
etoposide
Given IV
ifosfamide
Given IV
vincristine sulfate
Given IV
conventional surgery
Given to patients deemed to require it
radiation therapy
Given to patients deemed to require it
Group 2, arm II
Patients undergo 2 additional courses of VIDE induction chemotherapy (courses 5 and 6). Some patients may then undergo surgical resection of the tumor. All patients receive VAI chemotherapy as in group 1 for 1 course. Patients then receive high-dose chemotherapy comprising oral busulfan every 6 hours on days -6 to -3 and melphalan IV over 30 minutes on day -2. Patients receive autologous PBSC IV on day 0. Patients with unresectable, partially resected, or inadequately resected disease undergo concurrent radiotherapy 5 days a week for at least 5 weeks.
dactinomycin
Given IV
busulfan
Given orally and IV
doxorubicin hydrochloride
Given IV
etoposide
Given IV
ifosfamide
Given IV
melphalan
Given orally and IV
vincristine sulfate
Given IV
autologous hematopoietic stem cell transplantation
Given IV
conventional surgery
Given to patients deemed to require it
radiation therapy
Given to patients deemed to require it
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
dactinomycin
Given IV
busulfan
Given orally and IV
doxorubicin hydrochloride
Given IV
etoposide
Given IV
ifosfamide
Given IV
melphalan
Given orally and IV
vincristine sulfate
Given IV
autologous hematopoietic stem cell transplantation
Given IV
conventional surgery
Given to patients deemed to require it
radiation therapy
Given to patients deemed to require it
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed tumor of the Ewing's family of bone or soft tissue
* Ewing's sarcoma
* Peripheral primitive neuroectodermal tumor
* Disease meeting one of the following criteria:
* Resectable localized disease (tumor volume less than 200 mL)
* Localized disease previously resected at diagnosis
* Unresectable disease (at least 200 mL tumor volume) but radiotherapy as local control can be delayed
* Localized disease with early radiotherapy required
* Pulmonary and/or pleural metastases only
* Extrapulmonary/pleural metastases (skeleton, bone marrow, lymph nodes)
* No more than 45 days since definitive biopsy
PATIENT CHARACTERISTICS:
Age:
* Under 50
Performance status:
* Not specified
Life expectancy:
* Not specified
Hematopoietic:
* Not specified
Hepatic:
* Not specified
Renal:
* Renal function normal
* Glomerular filtration rate at least 60 mL/min
Cardiovascular:
* Normal cardiac function
* Fractional shortening at least 29%
* Ejection fraction at least 40%
Other:
* No medical, psychiatric, or social condition that would preclude study participation
PRIOR CONCURRENT THERAPY:
Biologic therapy:
* Not specified
Chemotherapy:
* No prior chemotherapy
Endocrine therapy:
* Not specified
Radiotherapy:
* Not specified
Surgery:
* See Disease Characteristics
49 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Cancer and Leukaemia Group
OTHER
Societe Francaise Oncologie Pediatrique
OTHER
European Organisation for Research and Treatment of Cancer - EORTC
NETWORK
German Society for Pediatric Oncology and Hematology GPOH gGmbH
OTHER
Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria
OTHER
Swiss Cancer Institute
OTHER
EBMT Solid Tumors Working Party
OTHER
Children's Oncology Group
NETWORK
University of Leicester
OTHER
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan W. Craft, MD
Role: STUDY_CHAIR
Sir James Spence Institute of Child Health at Royal Victoria Infirmary
Ian J. Lewis, MD
Role: STUDY_CHAIR
Leeds Cancer Centre at St. James's University Hospital
Odile Oberlin, MD
Role: STUDY_CHAIR
Gustave Roussy, Cancer Campus, Grand Paris
Ian R. Judson, MA, MD, FRCP
Role:
Institute of Cancer Research, United Kingdom
Heribert F. Juergens, MD
Role: STUDY_CHAIR
University Hospital Muenster
Helmut Gadner, MD, FRCPG
Role: STUDY_CHAIR
St. Anna Kinderkrebsforschung
G. Ulrich Exner, MD
Role: STUDY_CHAIR
Balgrist Universitaetsklinik
Ruth Ladenstein, MD
Role: STUDY_CHAIR
St. Anna Kinderkrebsforschung
Douglas Hawkins, MD
Role: STUDY_CHAIR
Seattle Children's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UAB Comprehensive Cancer Center
Birmingham, Alabama, United States
Phoenix Children's Hospital
Phoenix, Arizona, United States
Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
City of Hope Comprehensive Cancer Center
Duarte, California, United States
Childrens Hospital Los Angeles
Los Angeles, California, United States
Southern California Permanente Medical Group
Los Angeles, California, United States
Lucile Packard Children's Hospital at Stanford University Medical Center
Palo Alto, California, United States
Kaiser Permanente Medical Center - Oakland
Sacramento, California, United States
Rady Children's Hospital - San Diego
San Diego, California, United States
UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
Children's Hospital Colorado Center for Cancer and Blood Disorders
Aurora, Colorado, United States
Alfred I. duPont Hospital for Children
Wilmington, Delaware, United States
Children's National Medical Center
Washington D.C., District of Columbia, United States
Nemours Children's Clinic
Jacksonville, Florida, United States
University of Miami Sylvester Comprehensive Cancer Center - Miami
Miami, Florida, United States
Nemours Children's Clinic - Orlando
Orlando, Florida, United States
Nemours Children's Clinic - Pensacola
Pensacola, Florida, United States
All Children's Hospital
St. Petersburg, Florida, United States
St. Joseph's Cancer Institute at St. Joseph's Hospital
Tampa, Florida, United States
Kaplan Cancer Center at St. Mary's Medical Center
West Palm Beach, Florida, United States
AFLAC Cancer Center and Blood Disorders Service of Children's Healthcare of Atlanta - Egleston Campus
Atlanta, Georgia, United States
Cancer Research Center of Hawaii
Honolulu, Hawaii, United States
Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, United States
University of Chicago Cancer Research Center
Chicago, Illinois, United States
Saint Jude Midwest Affiliate
Peoria, Illinois, United States
Simmons Cooper Cancer Institute
Springfield, Illinois, United States
Holden Comprehensive Cancer Center at University of Iowa
Iowa City, Iowa, United States
Kosair Children's Hospital
Louisville, Kentucky, United States
Children's Hospital of New Orleans
New Orleans, Louisiana, United States
Alvin and Lois Lapidus Cancer Institute at Sinai Hospital
Baltimore, Maryland, United States
Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute
Boston, Massachusetts, United States
Hurley Medical Center
Flint, Michigan, United States
Helen DeVos Children's Hospital at Spectrum Health
Grand Rapids, Michigan, United States
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, United States
Bronson Methodist Hospital
Kalamazoo, Michigan, United States
Breslin Cancer Center at Ingham Regional Medical Center
Lansing, Michigan, United States
CCOP - Duluth
Duluth, Minnesota, United States
Children's Hospitals and Clinics of Minnesota - Minneapolis
Minneapolis, Minnesota, United States
Masonic Cancer Center at University of Minnesota
Minneapolis, Minnesota, United States
Mayo Clinic Cancer Center
Rochester, Minnesota, United States
Children's Hospitals and Clinics of Minnesota - St. Paul
Saint Paul, Minnesota, United States
University of Mississippi Cancer Clinic
Jackson, Mississippi, United States
Children's Mercy Hospital
Kansas City, Missouri, United States
Siteman Cancer Center at Barnes-Jewish Hospital - Saint Louis
St Louis, Missouri, United States
CCOP - Nevada Cancer Research Foundation
Las Vegas, Nevada, United States
Hackensack University Medical Center Cancer Center
Hackensack, New Jersey, United States
Roswell Park Cancer Institute
Buffalo, New York, United States
Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center
New York, New York, United States
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, United States
SUNY Upstate Medical University Hospital
Syracuse, New York, United States
Albert Einstein Cancer Center at Albert Einstein College of Medicine
The Bronx, New York, United States
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, United States
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, United States
Duke Cancer Institute
Durham, North Carolina, United States
Leo W. Jenkins Cancer Center at ECU Medical School
Greenville, North Carolina, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States
Rainbow Babies and Children's Hospital
Cleveland, Ohio, United States
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
Nationwide Children's Hospital
Columbus, Ohio, United States
Dayton Children's - Dayton
Dayton, Ohio, United States
Toledo Hospital
Toledo, Ohio, United States
Tod Children's Hospital
Youngstown, Ohio, United States
Oklahoma University Cancer Institute
Oklahoma City, Oklahoma, United States
Legacy Emanuel Children's Hospital
Portland, Oregon, United States
Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania, United States
Penn State Children's Hospital
Hershey, Pennsylvania, United States
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania, United States
Greenville Hospital Cancer Center
Greenville, South Carolina, United States
Avera Cancer Institute
Sioux Falls, South Dakota, United States
East Tennessee Children's Hospital
Knoxville, Tennessee, United States
Texas Tech University Health Sciences Center School of Medicine - Amarillo
Amarillo, Texas, United States
Driscoll Children's Hospital
Corpus Christi, Texas, United States
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, United States
Cook Children's Medical Center - Fort Worth
Fort Worth, Texas, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Methodist Children's Hospital of South Texas
San Antonio, Texas, United States
Primary Children's Medical Center
Salt Lake City, Utah, United States
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Inova Fairfax Hospital
Falls Church, Virginia, United States
Children's Hospital of The King's Daughters
Norfolk, Virginia, United States
Children's Hospital and Regional Medical Center - Seattle
Seattle, Washington, United States
Providence Cancer Center at Sacred Heart Medical Center
Spokane, Washington, United States
Mary Bridge Children's Hospital and Health Center - Tacoma
Tacoma, Washington, United States
West Virginia University Health Sciences Center - Charleston
Charleston, West Virginia, United States
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, United States
Marshfield Clinic - Marshfield Center
Marshfield, Wisconsin, United States
Midwest Children's Cancer Center at Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
Children's Hospital at Westmead
Westmead, New South Wales, Australia
Royal Children's Hospital
Brisbane, Queensland, Australia
Women's and Children's Hospital
North Adelaide, South Australia, Australia
Princess Margaret Hospital for Children
Perth, Western Australia, Australia
University of Alberta Hospital
Edmonton, Alberta, Canada
Children's and Women's Hospital of British Columbia
Vancouver, British Columbia, Canada
CancerCare Manitoba
Winnipeg, Manitoba, Canada
Janeway Children's Health and Rehabilitation Centre
St. John's, Newfoundland and Labrador, Canada
IWK Health Centre
Halifax, Nova Scotia, Canada
Hospital for Sick Children
Toronto, Ontario, Canada
Hopital Sainte Justine
Montreal, Quebec, Canada
Centre Hospitalier Universitaire de Quebec
Québec, Quebec, Canada
Saskatoon Cancer Centre at the University of Saskatchewan
Saskatoon, Saskatchewan, Canada
Starship Children's Health
Auckland, , New Zealand
San Jorge Children's Hospital
Santurce, , Puerto Rico
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Clinical Trials Office - UAB Comprehensive Cancer Center
Role: primary
Jessica Boklan
Role: primary
Clinical Trial Office - Arkansas Cancer Research Center at Uni
Role: primary
Clinical Trials Office - City of Hope Comprehensive Cancer Cen
Role: primary
Leo Mascarenhas
Role: primary
Robert M. Cooper
Role: primary
Neyssa M. Marina
Role: primary
Vincent A. Kiley
Role: primary
Clinical Trials Office - Rady Children's Hospital - San Diego
Role: primary
Clinical Trials Office - UCSF Helen Diller Family Comprehensi
Role: primary
Kelly W. Maloney
Role: primary
Clinical Trials Office - Alfred I. duPont Hospital for Childre
Role: primary
Clinical Trials Office - Children's National Medical Center
Role: primary
Eric S. Sandler
Role: primary
University of Miami Sylvester Comprehensive Cancer Center Clin
Role: primary
Ramamoorthy Nagasubramanian
Role: primary
Jeffrey H. Schwartz
Role: primary
Gregory A. Hale
Role: primary
Clinical Trials Office - St. Joseph's Cancer Institute
Role: primary
Narayana Gowda
Role: primary
Todd M. Cooper
Role: primary
Clinical Trials Office - Cancer Research Center of Hawaii
Role: primary
Eugenia Chang
Role: primary
Clinical Trials Office - University of Chicago Cancer Research
Role: primary
Pedro A. De Alarcon
Role: primary
Clinical Trials Office - Simmons Cooper Cancer Institute
Role: primary
Cancer Information Service
Role: primary
Clinical Trials Office - Children's Hospital of New Orleans
Role: primary
Joseph M. Wiley
Role: primary
Carlos Rodriguez-Galindo
Role: primary
Clinical Trials Office - Hurley Medical Center
Role: primary
Clinical Trials Office - Helen DeVos Children's Hospital
Role: primary
Clincial Trials Office - Van Elslander Cancer Center at St. Jo
Role: primary
Jeffrey S. Lobel
Role: primary
Clinical Trials Office - Breslin Cancer Center at Ingham Regio
Role: primary
Contact Person
Role: primary
Clinical Trials Office - Children's Hospitals and Clinics of M
Role: primary
Clinical Trials Office - Masonic Cancer Center at University o
Role: primary
Clinical Trials Office - All Mayo Clinic Locations
Role: primary
Contact Person
Role: primary
Gail C. Megason
Role: primary
Maxine L. Hetherington
Role: primary
Robert J. Hayashi
Role: primary
Jonathan Bernstein
Role: primary
Clinical Trials Office - Hackensack University Medical Center
Role: primary
Clinical Trials Office - Roswell Park Cancer Institute
Role: primary
Clinical Trials Office - Herbert Irving Comprehensive Cancer C
Role: primary
Lisa R. Hackney
Role: primary
Clinical Trials Office - SUNY Upstate Medical University Hospi
Role: primary
Clinical Trials Office - Albert Einstein Cancer Center at Albe
Role: primary
Clinical Trials Office - Blumenthal Cancer Center at Carolinas
Role: primary
Clinical Trials Office - Presbyterian Cancer Center at Presbyt
Role: primary
Clinical Trials Office - Duke Cancer Institute
Role: primary
Clinical Trials Office - Leo W. Jenkins Cancer Center at ECU M
Role: primary
Clinical Trials Office - Cincinnati Children's Hospital Medica
Role: primary
Yousif (Joe) H. Matloub
Role: primary
Clinical Trials Office - Cleveland Clinic Taussig Cancer Cente
Role: primary
Laura T. Martin
Role: primary
Emmett H. Broxson
Role: primary
Clinical Trials Office - Toledo Hospital
Role: primary
Clinical Trials Office - Tod Children's Hospital
Role: primary
Rene Y. McNall-Knapp
Role: primary
Clinical Trials Office - Legacy Emanuel Children's Hospital
Role: primary
Philip M. Monteleone
Role: primary
John F. Kuttesch
Role: primary
Elizabeth Fox
Role: primary
Clinical Trials Office - Children's Hospital of Pittsburgh
Role: primary
Clinical Trials Office - Greenville Hospital Cancer Center
Role: primary
Contact Person
Role: primary
Ray C. Pais
Role: primary
Osvaldo Regueira
Role: primary
Clinical Trials Office - Driscoll Children's Hospital
Role: primary
Clinical Trials Office - Simmons Comprehensive Cancer Center a
Role: primary
Clinical Trials Office - Cook's Children's Medical Center
Role: primary
Anne-Marie R. Langevin
Role: primary
Jaime Estrada
Role: primary
Phillip E. Barnette
Role: primary
Kimberly P. Dunsmore
Role: primary
Clinical Trials Office - Inova Fairfax Hospital
Role: primary
Eric J. Lowe
Role: primary
Julie R. Park
Role: primary
Judy L. Felgenhauer
Role: primary
Robert G. Irwin
Role: primary
Allen R. Chauvenet
Role: primary
Clinical Trials Office - St. Vincent Hospital Regional Cancer
Role: primary
Clinical Trials Office - Marshfield Clinic - Marshfield Center
Role: primary
Michael E. Kelly
Role: primary
Geoffrey B. McCowage
Role: primary
Helen Irving
Role: primary
Maria L. Kirby
Role: primary
Catherine H. Cole
Role: primary
Sunil Jayantilal' S. Desai
Role: primary
Caron Strahlendorf
Role: primary
Rochelle A. Yanofsky
Role: primary
Lisa Anne B. Goodyear
Role: primary
Margaret C. Yhap
Role: primary
Sylvain Baruchel
Role: primary
Yvan Samson
Role: primary
Bruno Michon
Role: primary
Christopher Mpofu
Role: primary
Lochie R. Teague
Role: primary
Luis A. Clavell
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Ladenstein R, Potschger U, Le Deley MC, Whelan J, Paulussen M, Oberlin O, van den Berg H, Dirksen U, Hjorth L, Michon J, Lewis I, Craft A, Jurgens H. Primary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trial. J Clin Oncol. 2010 Jul 10;28(20):3284-91. doi: 10.1200/JCO.2009.22.9864. Epub 2010 Jun 14.
Le Deley MC, Delattre O, Schaefer KL, Burchill SA, Koehler G, Hogendoorn PC, Lion T, Poremba C, Marandet J, Ballet S, Pierron G, Brownhill SC, Nesslbock M, Ranft A, Dirksen U, Oberlin O, Lewis IJ, Craft AW, Jurgens H, Kovar H. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol. 2010 Apr 20;28(12):1982-8. doi: 10.1200/JCO.2009.23.3585. Epub 2010 Mar 22.
Juergens C, Weston C, Lewis I, Whelan J, Paulussen M, Oberlin O, Michon J, Zoubek A, Juergens H, Craft A. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer. 2006 Jul;47(1):22-9. doi: 10.1002/pbc.20820.
Stork T, Ranft A, Aigner C, Jurgens H, Ladenstein RL, Timmermann B, Van den Berg H, Dirksen U, Collaud S. Primary Mediastinal Ewing's Sarcoma: Post Hoc Analysis from Two International Multicenter Prospective Randomized Trials. Cancers (Basel). 2025 Jan 2;17(1):118. doi: 10.3390/cancers17010118.
Rechl V, Ranft A, Bhadri V, Brichard B, Collaud S, Cyprova S, Eich H, Ek T, Gelderblom H, Hardes J, Haveman LM, Hartmann W, Hauser P, Heesen P, Jurgens H, Kanerva J, Kuhne T, Raciborska A, Rascon J, Streitburger A, Uhlenbruch Y, Timmermann B, Kersting J, Pham MT, Dirksen U. Factors Influencing the Outcome of Patients with Primary Ewing Sarcoma of the Sacrum. Sarcoma. 2024 Mar 16;2024:4751914. doi: 10.1155/2024/4751914. eCollection 2024.
Corvest V, Marec-Berard P, Lervat C, Pacquement H, Toulmonde M, Gentet JC, Laurence V, Cleirec M, Mansuy L, Bompas E, Castex MP, Taque S, Filhon B, Tabone MD, Verite C, Entz-Werle N, Saumet L, Guimard G, Pondrom M, Chevreau C, Flandrin J, Duranteau L, Rousset-Jablonski C, Brugieres L, Jimenez M, Le Deley MC, Gaspar N, Fresneau B. Late toxicity comparison of alkylating-based maintenance regimen with cyclophosphamide (VAC) vs ifosfamide (VAI) in Ewing sarcoma survivors treated in the randomized clinical trial Euro-EWING99-R1 in France. Int J Cancer. 2023 Apr 15;152(8):1659-1667. doi: 10.1002/ijc.34326. Epub 2022 Oct 31.
Dirksen U, Brennan B, Le Deley MC, Cozic N, van den Berg H, Bhadri V, Brichard B, Claude L, Craft A, Amler S, Gaspar N, Gelderblom H, Goldsby R, Gorlick R, Grier HE, Guinbretiere JM, Hauser P, Hjorth L, Janeway K, Juergens H, Judson I, Krailo M, Kruseova J, Kuehne T, Ladenstein R, Lervat C, Lessnick SL, Lewis I, Linassier C, Marec-Berard P, Marina N, Morland B, Pacquement H, Paulussen M, Randall RL, Ranft A, Le Teuff G, Wheatley K, Whelan J, Womer R, Oberlin O, Hawkins DS; Euro-E.W.I.N.G. 99 and Ewing 2008 Investigators. High-Dose Chemotherapy Compared With Standard Chemotherapy and Lung Radiation in Ewing Sarcoma With Pulmonary Metastases: Results of the European Ewing Tumour Working Initiative of National Groups, 99 Trial and EWING 2008. J Clin Oncol. 2019 Dec 1;37(34):3192-3202. doi: 10.1200/JCO.19.00915. Epub 2019 Sep 25.
Le Deley MC, Paulussen M, Lewis I, Brennan B, Ranft A, Whelan J, Le Teuff G, Michon J, Ladenstein R, Marec-Berard P, van den Berg H, Hjorth L, Wheatley K, Judson I, Juergens H, Craft A, Oberlin O, Dirksen U. Cyclophosphamide compared with ifosfamide in consolidation treatment of standard-risk Ewing sarcoma: results of the randomized noninferiority Euro-EWING99-R1 trial. J Clin Oncol. 2014 Aug 10;32(23):2440-8. doi: 10.1200/JCO.2013.54.4833. Epub 2014 Jun 30.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EURO-EWING-INTERGROUP-EE99
Identifier Type: -
Identifier Source: secondary_id
EBMT-INTERGROUP-EE99
Identifier Type: -
Identifier Source: secondary_id
EORTC-62981
Identifier Type: -
Identifier Source: secondary_id
GPOH-AUSTRIA-INTERGROUP-EE99
Identifier Type: -
Identifier Source: secondary_id
GPOH-GERMANY-INTERGROUP-EE99
Identifier Type: -
Identifier Source: secondary_id
SFOP-INTERGROUP-EE99
Identifier Type: -
Identifier Source: secondary_id
SWS-SAKK-INTERGROUP-EE99
Identifier Type: -
Identifier Source: secondary_id
CCLG-INTERGROUP-EE99
Identifier Type: -
Identifier Source: secondary_id
COG-AEWS0331
Identifier Type: -
Identifier Source: secondary_id
EU-20213
Identifier Type: -
Identifier Source: secondary_id
CDR0000068608
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.